2. Indication and suitability to receive palliative radiotherapy to the thorax (30Gy/10).

3. Receiving or planned to receive nivolumab or pembrolizumab

4. Prior history of systemic chemotherapy is permitted given a washout period of 4 weeks

5. Age 18 or older

6. ECOG Performance Status 0-2

7. Life expectancy greater than 3 months

8. Able and willing to provide informed consent

9. Able to complete patient reported outcome questionnaires

1. Contraindications to radiotherapy, including a history of SLE, systemic scleroderma, IPF, ataxia telangiectasia

2. Previous history of thoracic radiotherapy with an overlapping field

3. Previous history of checkpoint inhibitor related pneumonitis or esophagitis

4. Pregnancy

Palliative Thoracic ImmunoRT